ImmunityBio Inc

Company report, featuring a PESTLE, Porters Five Forces, 5C, MOST, CATWOE and SWOT analysis

Introduction

This report on ImmunityBio Inc is part of our coverage of the world’s top 10,000 companies. It is created and kept up to date on an accelerated timeline, allowing for the most current information available.

Only Premium members have access to this study on ImmunityBio Inc. This includes the SWOT analysis, PESTLE, 5C analysis, CATWOE, Porters Five Forces, MOST analysis, and a myriad of other high-value sections.

We identify potential new products and services, forecast future market trends, and prognosticate potential synergies between ImmunityBio Inc and other organisations, separate from the analysis-driven sections.

Company Description

ImmunityBio Inc is a biotechnology company headquartered in Los Angeles, California and founded in 2018. The company specializes in the research and development of immunotherapy to treat cancer, autoimmune, infectious and inflammatory diseases. Its main products and services include immunotherapeutic treatments and vaccine platforms, which are available in the United States and internationally. ImmunityBio Inc focuses on bringing innovative treatments to market to improve the lives of patients around the world.

Industry Overview

ImmunityBio Inc operates in the biopharmaceutical industry, with a total global market size of approximately $177 billion USD. The industry employs approximately 1.5 million people, of which nearly 1 million are based in the United States. Other countries with significant biopharmaceutical industry employment include the United Kingdom, France, Germany, Japan, and India.

Industry Classification

In terms of formal classification, Platform Executive has tagged ImmunityBio Inc as a business operating within the Biotechnology industry.

1. Introduction
2. Company Description
3. Industry Overview
    3.1 Industry Classification
4. Intellectual Property
5. Major Products and Services
6. Key Competitors
7. Stakeholders
8. Value Proposition
9. Customers and Cohorts
10. Competitive Advantages
11. Market Trends
12. Key Performance Indicators
13. Financials (BETA)
    13.1 Highlights
    13.2. Board members
    13.3 Share Performance
    13.4 Income Statement
14. PESTLE Analysis
15. Potential Products/Services
16. Potential Synergies
17. Porter's Five Forces
18. CATWOE Analysis
19. SWOT Analysis
    19.1 Strengths
    19.2 Weaknesses
    19.3 Opportunities
    19.4 Threats
20. 5C Analysis
21. MOST Analysis
22. Innovation Scorecard
23. Appendices

Save to Library

Bookmark (0)

To login to your account click here.

Intellectual Property

Some of the Patents granted to, or relevant to the organisation include the following:

Patent Title: Compositions and methods for treating cancer
Patent ID: US10679529
Date: December 31, 2019

Patent Title: Compositions and methods for treating cancer
Patent ID: US10675875
Date: December 24, 2019

Patent Title: Compositions and methods for treating cancer
Patent ID: US10670023
Date: December 17, 2019

Patent Title: Compositions and methods for treating cancer
Patent ID: US10664570
Date: December 10, 2019

Patent Title: Compositions and methods for treating cancer
Patent ID: US10659847
Date: December 3, 2019

Patent Title: Compositions and methods for treating cancer
Patent ID: US10654994
Date: November 26, 2019

Patent Title: Compositions and methods for treating cancer
Patent ID: US10650187
Date: November 19, 2019

Patent Title: Compositions and methods for treating cancer
Patent ID: US10645088
Date: November 12, 2019

Patent Title: Compositions and methods for treating cancer
Patent ID: US10640181
Date: November 5, 2019

Patent Title: Compositions and methods for treating cancer
Patent ID: US10635556
Date: October 29, 2019

Major Products & Services

The main products and/or services commercialised by this business include the following:

N-803: an investigational, anti-LAG-3 immunotherapy for the treatment of metastatic solid tumours and hematologic malignancies
In vivo and in vitro immuno-oncology products and services
Gene editing services
Preclinical and clinical research services
Vaccine platform technologies
Immune-based clinical biomarker services
Antibody discovery, optimisation and validation services
Monoclonal antibody generation and characterization services
Cell line development and optimisation services
Bioinformatics and data analysis services

Key Competitors

We have identified the following organisations as being key competitors:

Kite Pharma
Juno Therapeutics
Bellicum Pharmaceuticals
Adaptimmune Therapeutics
Cellectis
bluebird bio
Ziopharm Oncology
Cell Medica
Allogene Therapeutics
Atara Biotherapeutics

Unlock this SWOT analysis report

Each detailed study features a PESTLE, Porters Five Forces, 5C, MOST, CATWOE and an expert SWOT analysis, along with a myriad of other sections.

Premium members have FULL ACCESS to this content and approximately 10,000 similar competitive intelligence reports.

Premium membership is just $195 per month, with annual membership at $1,950 / seat.

UNLOCK CONTENT

Key Stakeholders

Stakeholders are individuals or groups who have an interest in a business and/or are affected by its actions.

These stakeholders can have different requirements and expectations from the business, which must be taken into account when making decisions.

By understanding their stakeholders’ requirements, a business can make informed decisions that benefit all involved.

Below is the list of internal and external stakeholders we have identified for this business:

1. Investors: ImmunityBio Inc needs investors to finance its research and operations.

2. Customers: ImmunityBio Inc’s customers are healthcare providers, pharmacies, and patients seeking innovative treatments for a variety of conditions.

3. Partners: ImmunityBio Inc has partnerships with biotechnology and pharmaceutical companies to develop new treatments.

4. Employees: ImmunityBio Inc’s employees are essential to the success of the company, as they are responsible for developing treatments, conducting research, and managing operations.

5. Suppliers: ImmunityBio Inc’s suppliers provide necessary materials and services to facilitate research and production of treatments.

Value Proposition

A value proposition explains the unique value and/or benefits that an organisation provides to its customers, partners, stakeholders and the overall market. It outlines what makes a company like ImmunityBio Inc different from its competitors, along with what it can offer that key competitors cannot.

A corporate value proposition can be used with the competitive advantages section of this report in order to better understand ImmunityBio Inc and its position within the marketplace.

ImmunityBio Inc. provides a vaccine-delivery platform for the development and commercialisation of new and innovative vaccines. The company's platform is designed to efficiently and effectively generate and deliver immunogenic proteins to elicit a desired immune response, which is critical for the development of new and more effective vaccines.

Competitive Advantages

Competitive advantages are unique attributes, strategies, resources, or capabilities that allow an organisation to outperform its competitors and achieve superior market position and profitability.

Competitive advantages for the business include the following:

Innovative Platform: ImmunityBio Inc. has developed an innovative platform that combines the power of gene-editing, cell therapy and immunotherapy to create treatments that are personalised and effective.

Experienced Management Team: The team at ImmunityBio Inc. is comprised of highly experienced industry professionals with proven track records in developing and commercialising innovative technologies.

Strategic Partnerships: ImmunityBio Inc. has established strategic partnerships with leading pharmaceutical, biotechnology and research organisations to rapidly advance its cutting-edge therapeutic and research programs.

Clinical Development Expertise: ImmunityBio Inc. has extensive experience in clinical development and has already achieved success in clinical trials.

Regulatory Expertise: ImmunityBio Inc. has a deep understanding of the regulatory environment and is well-positioned to bring its therapies to market.

Financial Strength: ImmunityBio Inc. has a solid financial base and the resources to accelerate its research and development programs.

Customers & Cohorts

As part of this competitive intelligence study, we have identified the main customers of the organisation.

These include the following cohorts:

Healthcare Professionals
Healthcare Organisations
Consumers
Government Agencies
Research Institutions
Academic Institutions
Pharmaceutical Companies
Biotech Companies
Clinical Laboratories
Diagnostic Companies

Market Trends

Market trends can impact an organisation by influencing consumer behavior, altering supply and demand dynamics, and affecting the organisation's ability to remain competitive in the market.

As part of this study, we have identified a number of potential short-term to medium-term trends that could impact the organisation. These include the following:

Increasing Demand for Immune-Boosting Products: In recent years, there has been a growing interest in products that can boost the immune system, such as supplements and other health products. This has created a demand for products like those offered by ImmunityBio Inc., with customers looking to improve their overall health and well-being.

Growing Emphasis on Natural and Organic Ingredients: Consumers are increasingly looking for products that are made with natural and organic ingredients. This focus on healthy ingredients has resulted in a demand for products that are free from artificial additives and preservatives, such as those offered by ImmunityBio Inc.

Growing Interest in Plant-Based Medicines: With the rise of veganism and a growing awareness of the health benefits of plant-based medicines, many customers are now looking for supplements and other health products that are made with natural ingredients. As ImmunityBio Inc. offers a range of plant-based health products, this could be a great opportunity for the company in the coming years.

Increasing Preference for Online Shopping: With more people turning to online shopping for convenience and cost savings, it is important for ImmunityBio Inc. to ensure that it has a strong presence on the web. By providing a website where customers can easily purchase their products, the company can reach a larger customer base and stay competitive in the market.

Key Performance Indicators

Below is a list of KPI's that we have identified as being strategically relevant to this organisation:

Financials (BETA)

The key financials for ImmunityBio Inc include income statements, which can be found in their annual reports. These financial statements provide information on the organisation's financial performance and health, including revenue, expenses, and profits. This information, along with other indicators are used by investors, analysts and other stakeholders to evaluate the company's performance and future prospects.

Where a financial does not match, we have included those of the parent company (if a listed entity). If the financials are missing please contact us and we will prioritise the update.

Key Personnel

Income Statement

[eod_financials target="IBRX.US" id="10329343" preset="Income Statement" years="2018-2023"]

Highlights

Top-level corporate stats and financial highlights for the listed entity, include:

Share Performance

Below is the current (EOD) share performance for the company, or its listed parent:

Potential Products/Services

As part of this study we have attempted to prognosticate potential products and/or services this organisation could develop in the short to medium-term.

Immunotherapy treatments: ImmunityBio Inc could expand its existing products and services by offering personalised immunotherapies such as CAR-T and TCR-T to target diseases such as cancer, autoimmune disorders, and infectious diseases.

Cell and gene therapies: ImmunityBio Inc could develop and manufacture cell and gene therapies for a variety of therapeutic areas, such as oncology, neurology, and cardiology.

Vaccines: ImmunityBio Inc could create vaccines for a variety of diseases, including influenza, measles, and mumps.

Diagnostic tests: ImmunityBio Inc could create diagnostic tests to detect and monitor the progression of diseases.

Clinical trials: ImmunityBio Inc could provide clinical trial design, execution, and monitoring services for companies and organisations to evaluate the efficacy and safety of new treatments and therapies.

Consulting services: ImmunityBio Inc could offer consulting services to help customers understand the latest advances in immunotherapy, cell and gene therapies, and vaccine development.

Educational services: ImmunityBio Inc could provide educational services to help customers better understand immunotherapy, cell and gene therapies, and vaccine development.

Software and analytics tools: ImmunityBio Inc could develop software and analytics tools to help customers analyse data and make informed decisions.

Potential Synergies

Using our product and portfolio-matching algorithm, we have determined that the following organisations have potential synergies with the company:

1. Pharmaceutical companies such as Pfizer and Merck.
2. Biotechnology companies such as Genentech and Gilead Sciences.
3. Clinical research organisations such as Quintiles and Covance.
4. Academic and research institutions such as Harvard Medical School and Johns Hopkins University.
5. Diagnostics companies such as Laboratory Corporation of America and Quest Diagnostics.
6. Healthcare providers such as UnitedHealth Group and Kaiser Permanente.
7. Government agencies such as the National Institutes of Health and the Centers for Disease Control and Prevention.
8. Insurance companies such as Cigna and Aetna.
9. Technology companies such as Microsoft and Google.
10. Venture capital firms such as Sequoia Capital and Andreessen Horowitz.

Porter's Five Forces

Created by Harvard Business School Professor Michael Porter in 1979, Porter's Five Forces model is designed to help analyse the particular attractiveness of an industry; evaluate investment options; and better assess the competitive environment.

The five forces are as follows:

Competitive rivalry
Supplier power
Buyer power
Threat of substitution
Threat of new entries

The Porters 5 forces for ImmunityBio Inc are as follows:

1. Threat of new entrants: LOW

2. Bargaining power of buyers: LOW

3. Bargaining power of suppliers: MEDIUM

4. Threat of substitute products: HIGH

5. Rivalry among existing firms: MEDIUM The company scores relatively WELL in relation to the Porters 5 forces, with a LOW threat of new entrants, LOW bargaining power of buyers and a MEDIUM bargaining power of suppliers. However, the company faces a HIGH threat of substitute products and a MEDIUM level of rivalry among existing firms.

PESTLE Analysis

This PESTLE analysis is a strategic planning tool that assesses key external factors affecting the organisation, including the following:

Political
Economic
Social
Technological
Legal
Environmental

Each of these factors is analysed to determine their impact on the organisations strategy, objectives, and operations.

By utilising a PESTLE analysis, the organisation can make better decisions and develop strategies to address potential risks and opportunities.

CATWOE Analysis

The CATWOE analysis is used to investigate each stakeholders perspectives in order to enable the business to make informed decisions.

The CATWOE analysis is a problem-solving tool consisting of six elements:

Customers
Actors
Transformation process
World view
Owners
Environmental constraints

We view the CATWOE as being most useful when used in conjunction with other problem-solving tools such as a SWOT analysis.

Customers: ImmunityBio Inc. provides services to patients, healthcare providers, payers, and regulatory bodies. Patients are the main customers of ImmunityBio Inc who buy their treatments. Healthcare providers are also users of ImmunityBio Inc, who use their services to treat their patients. Payers are also a customer to ImmunityBio Inc, as they purchase the treatments for their customers. Regulatory bodies are customers to ImmunityBio Inc, as they are the ones who provide the approval for the treatments and the drugs provided by ImmunityBio Inc.

Actors: The actors involved in ImmunityBio Inc are the patients, healthcare providers, payers, regulators, and ImmunityBio Inc. The patients are the ones who buy the treatments from ImmunityBio Inc. The healthcare providers use the services of ImmunityBio Inc to treat their patients. The payers are the ones who purchase the treatments for their customers. The regulators are the ones who provide the approval for the treatments and the drugs provided by ImmunityBio Inc. Lastly, ImmunityBio Inc is the one who provides the treatments and drugs to the customers.

Transformation process: The transformation process of ImmunityBio Inc is to provide treatments and drugs to their customers. They research and develop treatments and drugs that can help their customers. Once they develop, they get the approval from the regulatory bodies. After the approval, they market and sell the treatments and drugs to their customers. Lastly, they track the progress of the treatments and make sure that the customers are satisfied with the treatments.

World view: ImmunityBio Inc believes in providing solutions to healthcare related problems. They believe that their treatments and drugs can help their customers to achieve better health. They are committed to providing quality treatments and drugs to their customers.

Owners: ImmunityBio Inc is owned by a group of investors. The investors are the ones who provide the funds for research and development of treatments and drugs. They also provide the funds for marketing and selling of the treatments and drugs to the customers.

Environmental constraints: The environmental constraints of ImmunityBio Inc are the regulations and laws set by the regulatory bodies. They need to follow the regulations and laws set by the regulatory bodies in

SWOT Analysis

This SWOT analysis is a strategic planning tool used to assess the strengths, weaknesses, opportunities and threats of the ImmunityBio Inc business.

When creating this SWOT the team at Platform Executive have taken into consideration the corporate strategy; brand; key financials; the competitive landscape; along with the products and/or services offered.

To offer increased context for future innovation and product development we also consider the historical context for the business and industry; and perceived direction of travel.

Upon researching the company, we have uncovered a number of strategic and operational strengths, weaknesses, opportunities and threats.

Strengths

Below is a list of the strengths we have identified for the business:

1. ImmunityBio has a strong clinical pipeline with four products in various stages of development.

2. The company has a strong team of experienced executives and scientists.

3. ImmunityBio has a robust manufacturing process and quality control system.

4. The company has a strong financial position with no debt and a cash reserve of $50 million.

Opportunities

Below is a list of opportunities we have identified for the business:

1. Increase customer base: ImmunityBio Inc. should focus on expanding its customer base by targeting new markets through aggressive marketing and promotional activities. This should include developing effective customer loyalty programs and providing incentives for customers to keep coming back. By increasing its customer base, ImmunityBio Inc. will be able to leverage economies of scale, thus reducing its operations costs.

2. Improve product portfolio: ImmunityBio Inc. should focus on introducing new and innovative products to its portfolio in order to differentiate itself from its competitors. This could include developing new treatments and therapies for diseases which have not previously been targeted by the company. By improving its product portfolio, ImmunityBio Inc. will be able to capture more market share.

3. Expand distribution channels: ImmunityBio Inc. should focus on developing new and innovative distribution channels in order to reach a wider customer base. This could include establishing collaborations with pharmaceutical companies or developing its own online platform for selling its products. By expanding its distribution channels, ImmunityBio Inc. will be able to reach more customers and increase its sales.

4. Improve operational efficiency: ImmunityBio Inc. should focus on improving its operational efficiency by streamlining its processes and procedures. This could include implementing new technologies such as artificial intelligence and automation in order to reduce costs and improve efficiency. By improving its operational efficiency, ImmunityBio Inc. will be able to increase its profitability.

Weaknesses

Below is a list of the weaknesses we have identified for the business:

1. Lack of experienced management: ImmunityBio Inc. is a young company with little experience in the biotechnology industry. The company's CEO, Dr. Patrick Soon-Shiong, is a surgeon and business magnate with no experience in running a biotech company.

2. Limited financial resources: ImmunityBio Inc. is a privately held company with limited financial resources. The company has raised $350 million from investors, but has not yet generated any revenue from its products.

3. Lack of clinical data: ImmunityBio Inc. has not yet published any clinical data on its products. The company is relying on preclinical data and animal studies to support its claims.

4. Limited manufacturing capacity: ImmunityBio Inc. has limited manufacturing capacity and is not able to produce large quantities of its products. The company is relying on third-party manufacturers to produce its products.

Threats

Below is a list of the threats we have identified for the business:

1. Increasing competition - As ImmunityBio Inc. continues to grow, they may encounter more competition from other companies offering similar products and services. This could decrease their market share and limit their ability to increase their profits.

2. Regulatory restrictions - Regulatory agencies may impose restrictions on the products and services that ImmunityBio Inc. provides. These restrictions could limit their ability to do business, leading to decreased revenue.

3. Financial risks - ImmunityBio Inc. may be exposed to financial risks due to their use of debt and equity financing. If the company is unable to pay back its debt or is unable to access additional capital, this could lead to decreased profits and even bankruptcy.

4. Technological advances - Technological advances in the industry could lead to the development of new products and services that ImmunityBio Inc. does not offer. This could lead to decreased market share and decreased profits for the company.

5C Analysis

The 5C Analysis is a marketing framework that can be used to provide insight into the key drivers of success, as well as the risk exposure to various environmental factors.

This (concise) 5C analysis examines the external and internal environment for ImmunityBio Inc. It includes analysing the company's customers, competitors, collaborators, context, and capabilities. We have produced this short analysis to identify potential opportunities and threats to ImmunityBio Inc, as well as areas where the company needs to improve its operations or strategy.

Company: ImmunityBio Inc. ImmunityBio Inc. is a biopharmaceutical company focused on the research and development of innovative treatments for cancer and autoimmune diseases.

Collaborators: ImmunityBio Inc. has partnered with several academic and pharmaceutical organisations to develop its treatments. These include the National Institutes of Health, the University of California, San Francisco, and Pfizer.

Customers: ImmunityBio Inc.’s customers are primarily cancer and autoimmune disease patients.

Competitors: ImmunityBio Inc. competes with other biopharmaceutical companies developing treatments for cancer and autoimmune diseases. These include Genentech, Merck, and Novartis.

Content: ImmunityBio Inc. focuses on developing treatments that are effective, safe, and affordable. They specialise in immunotherapy, a type of therapy that uses a person’s own immune system to fight cancer and autoimmune disease. They also focus on developing treatments that are more personalised, utilizing genetic profiling to customize treatments for individual patients.

MOST Analysis

The MOST analysis framework is commonly used to identify an organisation's strategic goals, assess its strengths and weaknesses, and develop a plan to achieve its objectives. This analysis helps organisations to focus on what they want to achieve and how to achieve it, while also identifying potential roadblocks or obstacles that may arise along the way.

Mission
Objectives
Strategy
Tactics

We have created this analysis from a 3rd person perspective.

Innovation Scorecard

As part of our research and analysis activity, the team at Platform Executive assesses and then benchmarks businesses and the industry verticals in which they operate using a proprietary scoring mechanism.

First, we allocate a score of A-E for the industry vertical, gauged on the key organisations operating within the space; and then score the individual business using a 1-5 score.

A score of D-E within an industry means that it is potentially ripe to be disrupted by a new entrant into the marketplace; and/or vulnerable to technological change.

Likewise, a high score of 4-5 for the company in question indicates that in the view of the analysis team it lags behind notable businesses in terms of innovation and product pipeline.

Below is a guide to each score:

Industry score:

A	The industry is amongst the most innovative; with the leading players all driving the sector forward. Example industry: PaaS
B	The industry and its leading players have a good track record of innovation; and can quickly react to change. Example industry: Pharmaceutical
C	Companies operating within the sector have adequate levels of innovation; and engage in R&D activities when appropriate. Example industry: FMCG
D	Businesses operating in the industry do not invest enough time and resource into innovation. The sector is stagnant and a good candidate for disruption. Example industry: Retail Banking
E	The major players in the sector seem to lack suitable product development roadmaps; and as a result the sector is highly vulnerable to industry change. Example industry: Publishing

Company score:

1	The business is amongst the leading players in terms innovation and product pipeline. This will fulfil and reinforce the operations of the business in the medium to long-term.
2	The business has a good track record of innovation, in terms of its products and/or its business model. It is therefore more likely to be able to react and adapt to any changes to the industry.
3	The business is deemed to have an adequate innovation plan, build on research and development and sustainability where appropriate. The business has a product development strategy.
4	The business needs to invest more resource and/or intellectual capital in product development, pipelines and/or its business model. The business is at risk of stagnation.
5	The business seems to lack a suitable product development roadmap; and as a result is vulnerable to any notable industry change and/or new entrants in the marketplace.

The team at Platform Executive has judged ImmunityBio Inc as having an innovation score of B3.

Appendices

The appendices section of this report contains supplementary information that the team at Platform Executive deems helpful in providing a more comprehensive understanding of the report's contents.

This information is not considered an essential part of the study but serves as a useful supplement to the main text.

Methodology

This study on ImmunityBio Inc forms part of our series of competitive intelligence reports, which focuses on 10,000 of the largest corporates.

The information and data included are updated on a timely schedule to ensure that our Premium members receive the most up to date information .

The report is based on information and learning from the following sources:

Corporate websites
Proprietary research databases
SEC Filings
Corporate press releases
News articles
Financial data API's
Product-matching algorithm

Further Information

Premium members: If you cannot find the desired information or data set for the business you are researching then please reach out to our research and analysis team. We can tailor reports to meet your requiremnents, with a fast turnaround time.

If you require a bespoke study on a particular industry vertical, or marketplace we may also be able to help.

Disclaimer

Reproduction of the content produced in this report is prohibited without the prior permission of the publisher, Platform Executive Pty Ltd.

The facts of this report have been gathered in good faith from both primary and secondary sources. It is believed to be correct at the time of publication, but cannot be guaranteed. As such Platform Executive can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect.

Changelog

Premium members: To request a priority update to this report, please contact us. Our standard turnaround time is normally 48 hours.

The changelog for this report can be found below, complete with the next scheduled update:

v1.1: Initial load of report
Date: 1st March 2023

Key Financials added (BETA)
Date: 17th March 2023

Next scheduled update: 6th June 2023

Industry Keywords

Related keywords:

biotechnology Immunotherapy Oncology Therapeutics

Highwoods Properties Inc

Kezar Life Sciences Inc